Thank you for subscribing!
Finfeed Archived Jan 24, 2019
Yesterday, we outlined five ASX-listed Israeli tech stocks that are standing out. Here's another five to keep an eye on.
Finfeed Archived Jan 23, 2019
There are now some 17 Israel-born companies on the ASX, most of which are small caps, playing in a diverse range of tech-heavy markets, from telecommunications and digital media through to innovations in agriculture and legalised weed. We have scoped out 10 you should keep an eye on, and are starting with the following five.
Finfeed Archived Jan 09, 2019
ASX junior, BPH Energy (ASX:BPH), has released a positive update on its progress across its diversified medtech and biotech operations.
Finfeed Archived Jan 07, 2019
Imugene (ASX:IMU) has appointed world-renowned cancer researcher, Professor Michael Caligiuri — President of the City of Hope National Medical Center in LA — to its Scientific Advisory Board (SAB).
Get expert stock analysis direct in your inbox
Finfeed Archived Dec 17, 2018
Imugene (ASX:IMU) has met all study endpoints and produced positive top-line results from its Phase 1b study of its HER-Vaxx gastric cancer vaccine.
Finfeed Archived Nov 29, 2018
The Australian biotech industry is heavily supported by government and could reach $8 billion in revenue this year.
Finfeed Archived Nov 28, 2018
Medical diagnostics pioneer, Rhythm Biosciences (ASX: RHY), has made some senior management changes, appointing Glenn Gilbert as its CEO, effective immediately.
Finfeed Archived Nov 22, 2018
Antisense Therapeutics (ASX:ANP) CEO Mark Diamond speaks about ANP's relationship with biotech Ionis Pharmaceuticals and how ANP has grown up.
Finfeed Archived Nov 19, 2018
Immuron (ASX:IMC) has just appointed a well-credentialled CEO to help it develop and commercialise its many treatments of many gut mediated diseases.
Finfeed Archived Nov 13, 2018
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.
Finfeed Archived Nov 09, 2018
Imugene Limited (ASX:IMU) has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme. The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.
Finfeed Archived Oct 29, 2018
Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.
Finfeed Archived Oct 24, 2018
Last week, biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) spiked 217% in one day
Finfeed Archived Oct 22, 2018
It was a powerhouse week for biotech and pot-stocks, with high impact performances begging the question: is biotech finally back?
Finfeed Archived Oct 17, 2018
The biotech sector was yesterday led by biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) which ended the day 217% higher.
Finfeed Archived Oct 04, 2018
Antisense Therapeutics’ (ASX:ANP) ATL1102 to treat inflammation in boys with Duchenne Muscular Dystrophy (DMD) - one of the most common fatal genetic disorders. It’s caused by a mutation in the muscle dystrophin gene leading to severe progressive muscle loss and premature death.
Join Our Mailing List
